Analysis Of Income And Expense [Abstract]

BioGaia - Filing #5861821

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	1 422 718 SEK	—	—	—	—	—	—	1 296 506 SEK	—	—
Material income and expense [abstract]
Research and development expense	—	1 57 10 4 SEK	—	—	—	—	—	—	106 776 SEK	—	—
Finance income (cost)	—	24 4 4 8 SEK	—	—	—	—	—	—	25 731 SEK	—	—
Sales and marketing expense	—	422 657 SEK	—	—	—	—	—	—	36 3 25 6 SEK	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	22 565 SEK	22 565 SEK	—	22 565 SEK	—	—	9 762 SEK	9 762 SEK	—	9 762 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 SEK	373 953 SEK	22 565 SEK	351 3 8 8 SEK	373 953 SEK	0 SEK	0 SEK	9 762 SEK	355 590 SEK	3 65 35 2 SEK	355 590 SEK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	373 953 SEK	—	—	—	—	—	—	355 590 SEK	—	—
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests	—	- SEK	—	—	—	—	—	—	- SEK	—	—